Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Premium
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • PorteføljeInderes modelportefølje
  • Lær om investering
    • AnalyseskoleLær at læse og forstå aktieanalyse
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • InsidertransaktionerFølg købs- og salgsaktivitet fra virksomhedsinsidere
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Virtuel analytiker-chatStil spørgsmål og få AI-drevne investeringsindsigter med det samme
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Cell Impact Q3 2026: New opportunities despite continuing challenges

CISelskabsmeddelelse06.11.2026, 08.03
Download udgivelse

During the quarter, Cell Impact completed a rights issue that was 75 percent subscribed and generated proceeds of approximately SEK 40.2 million for the company before issue costs and repayment of bridge financing, including accrued interest.

Cell Impact signed an order with a leading US manufacturer of fuel cells and electrolyzers during the quarter. Deliveries were originally scheduled to take place on an ongoing basis over a two-year period. However, after the end of the quarter, the customer requested earlier deliveries, and final delivery is now scheduled for April 2027.

One significant development after the end of the quarter was the signing of an agreement with Toyota Tsusho Corporation, a global industrial and trading company based in Japan. At the request of a number of undisclosed customers, Cell Impact will perform forming tests on nanocrystalline titanium, a material that is already used by these customers in various mass production applications.

"Our focus is clear: we will continue to develop our existing customer relationships with the aim of moving into regular production, while expanding the use of our technology and expertise into new markets. The progress we have made to date now needs to be translated into orders, revenue and stronger cash flow," said Daniel Vallin, CEO of Cell Impact.

Financial summary:

  • Net sales totaled SEK 0.9 million (0.4).
  • The operating loss (EBIT) amounted to SEK -14.7 million (-21.7).
  • The Group's loss after financial items was SEK -10.6 million (-22.8).
  • Earnings per share attributable to the Parent Company's shareholders before and after dilution totaled SEK -0.01 (-0.14).
  • Debt/equity ratio was 86 percent (87) on the balance sheet date.
  • Cash flows from operating activities amounted to SEK -15.8 million (-19.6).
  • On the balance sheet date, the Group's cash and cash equivalents totaled SEK 11.2 million (6.7). As of November 5, 2026, the cash balance amounted to SEK 4.4 million.

This information is inside information that Cell Impact AB is obliged to make public pursuant to the EU Market Abuse Regulation.